Amgen, Merck & Co, Pfizer, Intermountain and McKesson were among the investors to jointly acquire a majority of the clinical trials software producer's shares.

The WuXi AppTec-backed hepatitis specialist replenished its coffers in a series A-plus round led by Hillhouse Capital fund GL Capital.

MS&AD Ventures and Mouro Capital helped privacy management technology provider Skyflow secure $45m while neurotherapeutics developer Cecerin revealed $40m from investors including Nestlé.

AstraZeneca, Eli Lilly and Sinopharm all achieved exits as the cancer therapy developer listed on the Hong Kong Stock Exchange at a reported valuation of nearly $1.1bn.

The cancer immunotherapy developer, which counts Novo and Lundbeck as investors, filed to raise up to $100m in its initial public offering.

Intelerad has bought the Mayo Clinic-backed medical image software developer to further expand its platform for reading, storing and sharing diagnostic imaging.

Alibaba participated in the cancer diagnostic kit provider's first funding round in over a year, pushing its overall funding past $230m.

Corporate-backed communications monetisation technology developer Matrixx Software raised $50m from Francisco Partners while cancer drug developer Abalos took the same in a BIVF-backed round.

The pharmacy operator more than doubled its stake in the primary care provider and now plans to accelerate a co-location rollout plan.

The Ascent Health and Wellness Solutions, Manipal Education and Medical Group, Medi Assist Healthcare Services and Prosus-backed online drugstore secured the funding at a $5.6bn valuation.